Apogee Therapeutics CMO Sells 10,900 Shares for $817,500
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Fool
- Significant Transaction Size: Apogee Therapeutics' Chief Medical Officer Carl Dambkowski executed an open-market sale of 10,900 shares for approximately $817,500 on December 4, 2025, marking the largest single transaction in the past 12 months, indicating a potential shift in confidence regarding the company's stock.
- Ownership Impact: This sale accounted for 3.87% of Dambkowski's direct holdings, significantly higher than the median 1.13% impact over the past year, suggesting an acceleration in his selling activity, which may reflect adjustments in expectations for future market conditions.
- Declining Holdings Trend: Dambkowski's direct ownership has decreased from 331,948 shares at the beginning of 2025 to 271,108 shares post-transaction, representing an 18.33% reduction, indicating a possible waning confidence in the company's future prospects.
- Positive Market Reaction: Although this transaction occurred against the backdrop of Apogee's stock surging over 45% by the end of 2025, Dambkowski's sale was part of a prearranged trading plan designed to mitigate insider trading risks, demonstrating his ongoing commitment to the company's future growth.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 95.00 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 78.950
Low
70.00
Averages
95.00
High
115.00
Current: 78.950
Low
70.00
Averages
95.00
High
115.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
